All Assays articles – Page 10
-
WhitepaperHandbook: Advanced flow cytometry handbook
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
-
NewsNew bacterial protein found to improve mitochondrial function
Protein released by C. burnetti interacts with antioxidising enzyme GPX4 to prevent cell damage and death.
-
WebinarBiophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterisation
Watch this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
-
WebinarBiophysical characterisation of binary and ternary drug-target complexes using the BRUKER SPR-32 PRO platform
Gain comprehensive insights into screening potential drugs, manipulating drug targets at the molecular level and employing techniques like SPR and X-ray crystallography for studying molecular interactions.
-
WebinarComplete aggregate and particle characterisation of protein, gene and cell therapies
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
-
WebinarUnlocking protein potential: liquid handling solutions for drug discovery
Watch this webinar to learn how PROTACs are revolutionising drug discovery, and the critical role protein purification plays in the production of therapeutic proteins.
-
Whitepaperebook: Maximizing preclinical confidence in target efficacy and safety
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
-
WhitepaperGuide: Screening biologic candidates with nanoDSF
Read this guide about nanoDSF for high-resolution measurements of thermal stability parameters, common CQAs for biologics developability assessment.
-
WhitepaperInfographic: Biologics stability in early development
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
-
WebinarSH2 domains as a target class in cancer and inflammation
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
-
WebinarBridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
The webinar will explore primary concerns in drug discovery development and why drugs fail.
-
WebinarFunctional assays for the development of agonistic antibodies
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
-
WebinarComplete CAR-T workflow solutions for research
Watch this webinar to get an overview of the CAR-T workflow and learn about the latest CAR-T research enabling tools that can accelerate your discovery.
-
WhitepaperCase study: Mitochondrial toxicity in drug discovery and development
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.
-
WhitepaperApplication note: Novel screening tools for TMEM175 drug discovery
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
-
Whitepaperebook: Fluorescence polarization assays
This ebook outlines the basics of fluorescence polarization and discusses the advantages and limitations of FP-based biochemical assays.
-
WebinarCardiac and vascular safety liabilities using totality of evidence approach
US-FDA recommend integration of both preclinical (S7B) and clinical (E14) data to improve risk assessment, reduce reliance on TQT clinical studies, streamlined drug-development, simplified decision-making processes, effective risk-communication.
-
Whitepaperebook: Choosing the right assay for PARP
This eBook describes different types of assays used to evaluate PARP activity and screening for specific inhibitors.
-
WebinarInnovations in organoid modelling for disease modelling and cell therapy
Watch our virtual panel, where you'll uncover the game-changing advantages of organoids over traditional 2D cultures. Our experts will explore the immense potential of organoids in oncology and immuno-oncology research.
-
WhitepaperBrochure: Overcome roadblocks in your PROTAC characterizations with Dianthus
Learn how Dianthus resolves common challenges you face during the characterization of PROTAC binary and ternary complexes and the determination of cooperativity.